What is Zacks Research’s Estimate for Neogen Q3 Earnings?

Neogen Co. (NASDAQ:NEOG) – Zacks Research lifted their Q3 2025 earnings per share estimates for shares of Neogen in a report released on Monday, March 3rd. Zacks Research analyst R. Department now forecasts that the company will earn $0.12 per share for the quarter, up from their previous estimate of $0.11. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s FY2025 earnings at $0.39 EPS.

Other equities research analysts have also recently issued reports about the stock. Piper Sandler restated a “neutral” rating and set a $13.00 price target (down from $16.50) on shares of Neogen in a report on Tuesday, January 21st. Guggenheim started coverage on Neogen in a research report on Thursday, December 19th. They set a “buy” rating and a $15.00 price objective for the company.

Neogen Price Performance

NASDAQ NEOG opened at $10.40 on Thursday. The company has a market cap of $2.26 billion, a P/E ratio of -4.75 and a beta of 1.27. Neogen has a 1 year low of $9.01 and a 1 year high of $18.58. The company has a current ratio of 3.77, a quick ratio of 2.46 and a debt-to-equity ratio of 0.33. The company has a fifty day simple moving average of $11.13 and a 200 day simple moving average of $13.57.

Neogen (NASDAQ:NEOG) last announced its earnings results on Friday, January 10th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.12. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The firm had revenue of $231.30 million during the quarter, compared to analysts’ expectations of $227.16 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. The company’s revenue was up .7% on a year-over-year basis.

Insider Activity at Neogen

In other news, CFO David H. Naemura purchased 14,800 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were purchased at an average cost of $11.11 per share, for a total transaction of $164,428.00. Following the completion of the purchase, the chief financial officer now directly owns 61,434 shares of the company’s stock, valued at approximately $682,531.74. The trade was a 31.74 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John Edward Adent acquired 23,035 shares of Neogen stock in a transaction on Thursday, January 16th. The stock was purchased at an average price of $11.03 per share, with a total value of $254,076.05. Following the transaction, the chief executive officer now directly owns 269,164 shares in the company, valued at approximately $2,968,878.92. This trade represents a 9.36 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.13% of the company’s stock.

Institutional Investors Weigh In On Neogen

Institutional investors have recently bought and sold shares of the business. Harbour Investments Inc. bought a new position in shares of Neogen during the 4th quarter worth about $27,000. Allspring Global Investments Holdings LLC lifted its stake in Neogen by 142.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock worth $33,000 after purchasing an additional 1,165 shares during the period. Blue Trust Inc. lifted its stake in Neogen by 196.7% during the fourth quarter. Blue Trust Inc. now owns 3,368 shares of the company’s stock worth $41,000 after purchasing an additional 2,233 shares during the period. Johnson Financial Group Inc. acquired a new stake in Neogen during the fourth quarter valued at approximately $43,000. Finally, Covestor Ltd grew its stake in shares of Neogen by 41.4% in the 4th quarter. Covestor Ltd now owns 4,103 shares of the company’s stock valued at $50,000 after purchasing an additional 1,202 shares during the period. Institutional investors and hedge funds own 96.73% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.